title: Improving glycaemic control of patients with Type 2 diabetes in a primary care setting: a French application of the Staged Diabetes Management programme.
abstract: OBJECTIVE
  To assess the impact of a French adaptation of the Staged Diabetes Management (SDM) programme on glycaemic control of people with Type 2 diabetes in primary care. Secondary endpoints were blood pressure, blood lipids, healthcare costs and quality of life.
  
  
  METHODS
  Prospective, randomized controlled study, of 1 years' duration. General practitioners (GPs) were recruited in four separate districts of a French region. They enrolled consecutive patients with Type 2 diabetes. GPs in the intervention group were educated in the SDM programme. GPs in the control group were asked to provide usual care. Healthcare costs were collected by medical departments of the Health Insurance systems. Quality of life was assessed with the Duke Health Profile.
  
  
  RESULTS
  Three hundred and forty patients enrolled by 57 GPs completed the study, 192 in the intervention group and 148 in the control group. Patients in the intervention group were managed more adequately in accordance with the guidelines (P < 0.05 for nine out of 10 items). HbA(1c) decreased by 0.31% in the intervention group and increased by 0.56% in the control group, resulting in a difference of 0.87% by the end of the study (P = 0.001). Blood pressure and blood lipids did not differ between groups. Occurrence of major complications was low and identical in both groups. Incremental costs during the study in the intervention group were 35 euros per patient per month, and this was not significantly different in comparison with the control group. Quality of life was not affected by the intervention.
  
  
  CONCLUSIONS
  Educating GPs in the French adaptation of the SDM programme improves glycaemic control in a primary care setting, without significantly increasing healthcare costs.
authors.affiliation: Diabetes Department, Sud Francilien Hospital, Corbeil-Essonnes, France. m.varroud-vial@worldonline.fr
authors.forename: M
authors.initials: M
authors.lastname: Varroud-Vial
authors.forename: D
authors.initials: D
authors.lastname: Simon
authors.forename: J
authors.initials: J
authors.lastname: Attali
authors.forename: I
authors.initials: I
authors.lastname: Durand-Zaleski
authors.forename: L
authors.initials: L
authors.lastname: Bera
authors.forename: C
authors.initials: C
authors.lastname: Attali
authors.forename: C
authors.initials: C
authors.lastname: Letondeur
authors.forename: K
authors.initials: K
authors.lastname: Strauss
authors.forename: C
authors.initials: C
authors.lastname: Petit
authors.forename: G
authors.initials: G
authors.lastname: Charpentier
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring / Q000379:methods; D001794:Blood Pressure / Q000502:physiology; D003365:Costs and Cost Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000191:economics / Q000628:therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000191:economics / Q000379:methods*; D011446:Prospective Studies; D011788:Quality of Life; D012017:Referral and Consultation; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin